Irofulven: Resurgence for alkylating therapy in cancer?

Cancer Biology and Therapy

Volumn 3, Issue 11, 2004, Pages 1143-1144

  Dent, Paul ^a,c   Grant, Steven ^b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alkylating agent; Bcl 2; Ionizing radiation; p53; Post mitotic; Signaling; Survival

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ALKYLATING AGENT; IROFULVEN; UNCLASSIFIED DRUG; PROTEIN BCL 2; SESQUITERPENE;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CELL CYCLE S PHASE; CYTOTOXICITY; DNA STRAND; HUMAN; HUMAN CELL; MITOSIS; MUSHROOM; NOTE; TUMOR CELL; TUMOR GROWTH; CELL CYCLE G1 PHASE; DRUG EFFECT; EDITORIAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; G1 PHASE; GENE EXPRESSION REGULATION; HUMANS; MITOSIS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; SESQUITERPENES;

EID: 22144446452     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.11.1306     Document Type: Note

References (10)

1. MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD. Preclinical antitumor activity of 6- hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997; 57:279-283.
2. Dick RA, Yu X, Kensler TW. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven. Clin Cancer Res 2004; 10:1492-9.
3. Poindessous V, Koeppel F, Raymond E, Comisso M, Waters SJ, Larsen AK. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res 2003; 9:2817-25.
4. Nasta SD, Hoff PM, George CS, Neubauer M, Cohen SC, Abbruzzese J, Winn R, Pazdur RM. Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. Am J Clin Oncol 2003; 26:132-4.
5. Pierson AS, Gibbs P, Richards J, Russ P, Eckhardt SG, Gonzalez R. A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. Invest New Drugs 2002; 20:357-62.
6. Koeppel F, Poindessous V, Lazar V, Raymond E, Sarasin A, Larsen AK. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res 2004; 10:5604-13.
7. Wang W, Waters SJ, MacDonald JR, Roth C, Shentu S, Freeman J, Von Hoff DD, Miller AR. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases. Anticancer Res 2002; 22:559-64.
8. Herzig MC, Trevino AV, Liang H, Salinas R, Waters SJ, MacDonald JR, Woynarowska BA, Woynarowski JM. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Biochem Pharmacol 2003; 65:503-13.
9. Wang J, Wiltshire T, Wang Y, Mikell C, Burks J, Cunningham C, Van Laar ES, Waters SJ, Reed E, Wang W. ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem 2004; 279:39584-92.
10. Woynarowska BA, Roberts K, Woynarowski JM, MacDonald JR, Herman TS. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res 2000; 154:429-38.